173 related articles for article (PubMed ID: 38577598)
1. B7-H3 suppresses CD8
Wu Y; Han W; Tang X; Liu J; Guo Z; Li Z; Cai C; Que L
J Cancer; 2024; 15(9):2505-2517. PubMed ID: 38577598
[TBL] [Abstract][Full Text] [Related]
2. The immunoregulatory protein B7-H3 promotes aerobic glycolysis in oral squamous carcinoma via PI3K/Akt/mTOR pathway.
Li Z; Liu J; Que L; Tang X
J Cancer; 2019; 10(23):5770-5784. PubMed ID: 31737114
[TBL] [Abstract][Full Text] [Related]
3. B7-H3 on breast cancer cell MCF7 inhibits IFN-γ release from tumour-infiltrating T cells.
Shao L; Yu Q; Xia R; Zhang J; Gu S; Yu D; Zhuang Z
Pathol Res Pract; 2021 Aug; 224():153461. PubMed ID: 34265738
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.
Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M
Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543
[TBL] [Abstract][Full Text] [Related]
5. B7-H3/CD276: An Emerging Cancer Immunotherapy.
Zhou WT; Jin WL
Front Immunol; 2021; 12():701006. PubMed ID: 34349762
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors.
Nunes-Xavier CE; Karlsen KF; Tekle C; Pedersen C; Øyjord T; Hongisto V; Nesland JM; Tan M; Sahlberg KK; Fodstad Ø
Oncotarget; 2016 Feb; 7(6):6891-901. PubMed ID: 26771843
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.
Shi W; Wang Y; Zhao Y; Kim JJ; Li H; Meng C; Chen F; Zhang J; Mak DH; Van V; Leo J; St Croix B; Aparicio A; Zhao D
Sci Transl Med; 2023 May; 15(695):eadf6724. PubMed ID: 37163614
[TBL] [Abstract][Full Text] [Related]
8. Fully human anti-B7-H3 recombinant antibodies inhibited tumor growth by increasing T cell infiltration.
Li L; Nian S; Liu Q; Zhang B; Jimu W; Li C; Huang Z; Hu Q; Huang Y; Yuan Q
Int Immunopharmacol; 2024 May; 132():111926. PubMed ID: 38552297
[TBL] [Abstract][Full Text] [Related]
9. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses.
Hashiguchi M; Kobori H; Ritprajak P; Kamimura Y; Kozono H; Azuma M
Proc Natl Acad Sci U S A; 2008 Jul; 105(30):10495-500. PubMed ID: 18650384
[TBL] [Abstract][Full Text] [Related]
10. The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.
Chang SR; Chou CH; Liu CJ; Lin YC; Tu HF; Chang KW; Lin SC
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983005
[TBL] [Abstract][Full Text] [Related]
11. PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.
Varki V; Ioffe OB; Bentzen SM; Heath J; Cellini A; Feliciano J; Zandberg DP
Cancer Immunol Immunother; 2018 May; 67(5):805-814. PubMed ID: 29484464
[TBL] [Abstract][Full Text] [Related]
12. B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.
Miyamoto T; Murakami R; Hamanishi J; Tanigaki K; Hosoe Y; Mise N; Takamatsu S; Mise Y; Ukita M; Taki M; Yamanoi K; Horikawa N; Abiko K; Yamaguchi K; Baba T; Matsumura N; Mandai M
Cancer Immunol Res; 2022 Jan; 10(1):56-69. PubMed ID: 34799346
[TBL] [Abstract][Full Text] [Related]
13. mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion.
Liu HJ; Du H; Khabibullin D; Zarei M; Wei K; Freeman GJ; Kwiatkowski DJ; Henske EP
Nat Commun; 2023 Mar; 14(1):1214. PubMed ID: 36869048
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo.
Zhou Z; Yu X; Chen Y; Tan X; Liu W; Hua W; Chen L; Zhang W
Clin Transl Oncol; 2023 Apr; 25(4):1067-1079. PubMed ID: 36512305
[TBL] [Abstract][Full Text] [Related]
15. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.
Chapoval AI; Ni J; Lau JS; Wilcox RA; Flies DB; Liu D; Dong H; Sica GL; Zhu G; Tamada K; Chen L
Nat Immunol; 2001 Mar; 2(3):269-74. PubMed ID: 11224528
[TBL] [Abstract][Full Text] [Related]
16. B7-H3, Negatively Regulated by miR-128, Promotes Colorectal Cancer Cell Proliferation and Migration.
Hu X; Xu M; Hu Y; Li N; Zhou L
Cell Biochem Biophys; 2021 Jun; 79(2):397-405. PubMed ID: 33743142
[TBL] [Abstract][Full Text] [Related]
17. MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
Deng M; Wu D; Zhang Y; Jin Z; Miao J
Gynecol Oncol; 2021 Jul; 162(1):190-199. PubMed ID: 33875234
[TBL] [Abstract][Full Text] [Related]
18. Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells.
Flem-Karlsen K; Tekle C; Andersson Y; Flatmark K; Fodstad Ø; Nunes-Xavier CE
Pigment Cell Melanoma Res; 2017 Sep; 30(5):467-476. PubMed ID: 28513992
[TBL] [Abstract][Full Text] [Related]
19. B7-H3 immunoregulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
[TBL] [Abstract][Full Text] [Related]
20. B7-H3 Promotes Pathogenesis of Autoimmune Disease and Inflammation by Regulating the Activity of Different T Cell Subsets.
Luo L; Zhu G; Xu H; Yao S; Zhou G; Zhu Y; Tamada K; Huang L; Flies AD; Broadwater M; Ruff W; van Deursen JM; Melero I; Zhu Z; Chen L
PLoS One; 2015; 10(6):e0130126. PubMed ID: 26065426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
